Boehringer Ingelheim Limited

Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
Telephone: +44 (0)1344 424 600
Fax: +44 (0)1344 741 298
WWW: http://www.boehringer-ingelheim.co.uk
Medical Information Direct Line: +44 (0)1344 741 286
Medical Information e-mail: medinfo@bra.boehringer-ingelheim.com
Summary of Product Characteristics last updated on the eMC: 17/09/2009
SPC Oramorph Oral Solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/09/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of Excipients
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Aug-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 2 has been updated to include information on excipients.

 

Section 6.1 has been updated regarding excipient names.

 

Section 10 date has been revised to August 2009

Updated on 25/08/2009 and displayed until 17/09/2009
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Apr-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 6.3 Shelf Life

The text 90 days has been replaced with the text 3 months in the second sentence of this section.

 

Section 6.4 Special Precautions for Storage

The text to protect from light has been added to the end of the second sentence of this section.

 

Section 6.5 Nature and Contents of Container

The text Registered Packs has been deleted as a header before the first paragraph of this section.

 

The Marketed Packs header and corresponding text has been deleted and replaced with the text Not all pack sizes may be marketed.

 

Section 10 Date of Revision of the Text

The date November 2008 has been replaced with the date April 2009.

Updated on 28/01/2009 and displayed until 25/08/2009
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5 - Pharmacological Properties
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Nov-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Oramorph Oral Solution SPC changes

  

Section 4.3 Contraindications

The words opiods and phaeochromatoma in the third paragraph of this section have been replaced with the correctly spelt versions i.e. opioids and phaeochromocytoma.

 

Section 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction

The word medicaments has been replaced with the words medicinal products in the header of this section.

 

New fifth and sixth paragraphs have been added.  Paragraph 5 begins with the words Interactions have been reported … and paragraph 6 begins with the words In a study involving healthy volunteers …

 

Section 5 Pharmacological Properties

The words have been put in upper case to align with the rest of the document’s main section headings.

 

Section 6 Pharmaceutical Particulars

The words have been put in upper case to align with the rest of the document’s main section headings.

 

Section 6.6 Special Precautions for Disposal

The words Instructions for Use/Handling have been replaced with the words Special Precautions for Disposal in the header of this section.

 

Administrative Data

The words Administrative Data have been deleted as a header between sections 6.6 and 7.

 

Section 7 Marketing Authorisation Holder

The words have been put in upper case to align with the rest of the document’s main section headings.

 

Section 8 Marketing Authorisation Number

The words have been put in upper case to align with the rest of the document’s main section headings.

  

Section 9 Date of First Authorisation/Renewal of the Authorisation

The words have been put in upper case to align with the rest of the document’s main section headings.

 

This section’s text now reads:

 

Date of first authorisation: 8th March 1988

Date of last renewal: 8th March 1993

 

as opposed to:

 

Date of first authorisation/renewal of the authorisation

08.03.88 / 08.03.93

 

Section 10 Date of Revision of the Text

The section header wording has been changed from Date of (partial) revision of the text to Date of revision of the text and put into upper case letters.

 

The date of revision has been updated from August 2008 to November 2008.

Updated on 22/09/2008 and displayed until 28/01/2009
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Aug-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Oramorph Oral Solution SPC changes

  

Section 4.3 – Contraindications

 

The words “Oramorph is contraindicated in patients known to be hypersensitive to morphine sulphate or to any other component of the product” have been added as a new paragraph 2.

 

Section 4.4 – Warnings and Precautions

 

The words “Hypersensitivity and anaphylactic reaction have both occurred with the use of Oramorph.  Care should be taken to elicit any history of allergic reactions to opiates” have been added as a final paragraph.

 

Section 4.8 – Undesirable Effects

 

The words “Immune system disorders: hypersensitivity reactions including anaphylaxis.  Urticaria, pruritis” have been added as a final paragraph i.e. after the “General” adverse reactions section.

 

Section 10 – Date of Revision of the Text

 

The words “July 2006” have been replaced with the words “August 2008”.

 

Updated on 23/03/2007 and displayed until 22/09/2008
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   07/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.2: Addition of patients with moderate-severe renal or hepatic impairment, or where sedation is undesirable
Section 4.3: Addition of  Morphine and some other opiods can induce the release of endogenous histamine and thereby stimulate catecholamine release making them unsuitable for use in patients with phaeochromatoma. Opioids are contraindicated in acute asthma exacerbations, see section 4.4 for information relating to use in controlled asthma.
Section 4.4: Rewritten/reworded.
Section 4.5: addition of new interactions.
Section 4.6: rewritten/reworded.
Section 4.7: Addition of This effect is even more enhanced, when used in combination with alcohol or CNS depressants. Patients should be warned not to drive or operate dangerous machinery after taking Oramorph.
Section 4.8: Rewritten/reworded.
Section 4.9: addition of naloxone caution,
Updated on 20/09/2005 and displayed until 23/03/2007
Reasons for adding or updating:
  • Change to section 1 - trade name
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 4 - Special Precautions for Storage
Updated on 18/07/2001 and displayed until 20/09/2005
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 22/03/2001 and displayed until 18/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 05/09/2000 and displayed until 22/03/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 26/01/2000 and displayed until 05/09/2000
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 26/01/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   morphine sulphate


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk